XOMA (NASDAQ:XOMA) Upgraded at BidaskClub

BidaskClub upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports.

A number of other analysts also recently commented on XOMA. Zacks Investment Research raised XOMA from a hold rating to a buy rating and set a $18.00 price target for the company in a research report on Saturday, August 15th. ValuEngine raised XOMA from a hold rating to a buy rating in a research report on Thursday, October 1st. Finally, Wedbush reaffirmed an outperform rating on shares of XOMA in a research report on Tuesday, August 25th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $25.67.

Shares of XOMA stock opened at $24.93 on Tuesday. The company has a market cap of $274.68 million, a PE ratio of -22.46 and a beta of 1.26. XOMA has a 52 week low of $14.14 and a 52 week high of $28.85. The business has a 50 day moving average price of $20.12 and a 200-day moving average price of $20.47. The company has a quick ratio of 4.63, a current ratio of 4.63 and a debt-to-equity ratio of 0.61.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.05. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.76 million. XOMA had a negative return on equity of 28.83% and a negative net margin of 102.23%. As a group, research analysts anticipate that XOMA will post -1.34 EPS for the current year.

In related news, Director Bvf Partners L. P/Il purchased 17,089 shares of the business’s stock in a transaction dated Wednesday, September 23rd. The stock was purchased at an average cost of $18.20 per share, with a total value of $311,019.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Value Fund L. P. Biotechnology purchased 51,368 shares of the business’s stock in a transaction dated Wednesday, September 23rd. The stock was bought at an average cost of $18.34 per share, with a total value of $942,089.12. Insiders acquired 220,689 shares of company stock valued at $4,113,639 over the last three months. Company insiders own 9.89% of the company’s stock.

Several institutional investors have recently bought and sold shares of XOMA. BVF Inc. IL boosted its holdings in shares of XOMA by 45.2% in the second quarter. BVF Inc. IL now owns 4,026,157 shares of the biotechnology company’s stock worth $79,557,000 after acquiring an additional 1,252,772 shares during the period. Point72 Asset Management L.P. bought a new stake in XOMA during the second quarter valued at $988,000. Invesco Ltd. bought a new stake in XOMA during the first quarter valued at $652,000. Opaleye Management Inc. boosted its stake in XOMA by 7.3% during the second quarter. Opaleye Management Inc. now owns 415,380 shares of the biotechnology company’s stock valued at $8,208,000 after buying an additional 28,380 shares during the period. Finally, Charles Schwab Investment Management Inc. bought a new stake in XOMA during the second quarter valued at $324,000. 57.21% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Read More: Marijuana Stocks

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.